[Prognosis of acute lymphoblastic leukemia in children. Results of the French protocol FRALLE 93]
- PMID: 11474564
[Prognosis of acute lymphoblastic leukemia in children. Results of the French protocol FRALLE 93]
Abstract
1,120 children were included in protocol FRALLE 93 from june 1993 to september 1998. Disease Free Survival for the all protocol is 78% +/- 3 and overall survival 83% +/- 3. Various clinical and laboratory features at the time of diagnosis have been correlated with prognosis. They provide a potential mean to stratify patients into treatment subgroups according their relative risk of treatment failure. The identification of these prognostic factors has been an essential element in the design of current therapeutic trials. Prognostic characteristics of childhood ALL include: age, white blood cell count, tumor burden, cytogénétics (chromosome count and chromosomal translocation), immunophenotype and early response to treatment. Molecular biology has been the revolution of the last two decades permitting the cloning of the genes involved in the leukemic process. Finally the new molecular techniques allow a sensitive diagnostic approach to minimal residual disease (MRD). The better detection of MRD must allow a more rational basis for therapeutic intensification for a subset of poor responder patients. A decrease in therapy of very good responders can also be envisaged.
Similar articles
-
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.J Clin Oncol. 2003 Mar 1;21(5):774-80. doi: 10.1200/JCO.2003.02.053. Epub 2003 Mar 1. J Clin Oncol. 2003. PMID: 12610173 Clinical Trial.
-
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.Haematologica. 2008 Nov;93(11):1658-65. doi: 10.3324/haematol.13291. Epub 2008 Oct 2. Haematologica. 2008. PMID: 18835836
-
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.Haematologica. 2002 Feb;87(2):154-66. Haematologica. 2002. PMID: 11836166 Clinical Trial.
-
Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].Eur J Cancer. 2005 Jul;41(11):1570-83. doi: 10.1016/j.ejca.2004.11.004. Epub 2005 Jan 5. Eur J Cancer. 2005. PMID: 16026693 Review.
-
[Minimal residual disease in childhood acute leukemias].Przegl Lek. 2006;63(1):41-3. Przegl Lek. 2006. PMID: 16892899 Review. Polish.
Cited by
-
Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998.Clin Transl Oncol. 2008 Feb;10(2):117-24. doi: 10.1007/s12094-008-0165-1. Clin Transl Oncol. 2008. PMID: 18258511 Clinical Trial.
-
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.Leukemia. 2020 Jun;34(6):1694-1700. doi: 10.1038/s41375-019-0670-y. Epub 2019 Dec 5. Leukemia. 2020. PMID: 31806872 Clinical Trial. No abstract available.
-
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111. Blood Cancer J. 2016. PMID: 27935576 Free PMC article. Clinical Trial.